Insulin resistance and endothelial dysfunction: Are epoxyeicosatrienoic acids the link?

Experimental and Clinical Cardiology

Volumn 14, Issue 2, 2009, Pages

  Mustafa, Sally ^a   Sharma, Vijay ^a   McNeill, John H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Endothelium; Epoxyeicosatrienoic acids; Insulin; Soluble epoxide hydrolase; Vasodilation

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 14,15 EPOXYEICOSAENOIC METHYLSULFONYLIMIDE; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; 5,6 EPOXYPROSTAGLANDIN E1; 8,9 EPOXYICOSATRIENOIC ACID; ACETYLCHOLINE; ANANDAMIDE; BETA NAPHTHOFLAVONE; BL 11282; BRADYKININ; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEXAMETHASONE; DOCOSAPENTAENOIC ACID; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; FLUINDOSTATIN; IMIDAZOLINE DERIVATIVE; INSULIN; MESYLIC ACID DERIVATIVE; METHACHOLINE; MEVINOLIN; NIFEDIPINE; PHENOBARBITAL; PHOSPHATIDYLINOSITOL; PROSTAGLANDIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; RECEPTOR PROTEIN; SULFAPHENAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD VESSEL TONE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISOMERISM; METABOLIC SYNDROME X; NONHUMAN; PANCREAS ISLET; PROTEIN SYNTHESIS INHIBITION; REVIEW; STIMULUS SECRETION COUPLING; STRUCTURE ANALYSIS; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 70350593993     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med 2007;262:173-183 (Pubitemid 47087632)
2. Muniyappa R, Quon MJ. Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care 2007;10:523-530 (Pubitemid 46934125)
3. Campbell WB, Gauthier KM. What is new in endothelium-derived hyperpolarizing factors? Curr Opin Nephrol Hypertens 2002;11:177-183
4. Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 2007;49:590-596 (Pubitemid 46263200)
5. Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi AA. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol 2001;280:H2470-7. (Pubitemid 32553286)
6. + channels. Circ 2001;103:1992-1998.
7. Larsen BT, Miura H, Hatoum OA, et al. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 2006;290:H491-9.
8. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000;87:992-998 (Pubitemid 30949215)
9. Imig JD, Zhao X, Zaharis CZ, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005;46:975-981
10. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydzrolase inhibitor, 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2005;46:842-848 (Pubitemid 44378259)
11. Falck JR, Manna S, Moltz J, Chacos N, Capdevila J. Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. Biochem Biophys Res Commun 1983;114:743-749
12. Sharoyko VV, Zaitseva II, Leibiger B, Efendić S, Berggren PO, Zaitsev SV. Arachidonic acid signaling is involved in the mechanism of imidazoline-induced KATP channel-independent stimulation of insulin secretion. Cell Mol Life Sci 2007;64:2985-2993 (Pubitemid 351152250)
13. Miller AW, Dimitropoulou C, Han G, White RE, Busija DW, Carrier GO. Epoxyeicosatrienoic acid-induced relaxation is impaired in insulin resistance. Am J Physiol Heart Circ Physiol 2001;281:H1524-31. (Pubitemid 32948195)
14. Park Y, Capobianco S, Gao X, Falck JR, Dellsperger KC, Zhang C. Role of EDHF in type 2 diabetes-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008;295:H1982-8.
15. Zeldin DC, Foley J, Boyle JE, et al. Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinol 1997;138:1338-1346 (Pubitemid 27089795)
16. Yoshida S, Hirai A, Tamura Y, Yoshida S. Possible involvement of arachidonic acid metabolites of cytochrome P450 monooxygenase pathway in vasopressin-stimulated glycogenolysis in isolated rat hepatocytes. Arch Biochem Biophys 1990;280:346-351 (Pubitemid 20221974)
17. Efanov AM, Zaitsev SV, Mest HJ, et al. The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic beta-cells in the absence of modulation of K(ATP) channel activity. Diabetes 2001;50:797-802.
18. Zhao X, Dey A, Romanko OP, et al. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2005;288:R188-96. (Pubitemid 40023930)
19. Katakam PV, Hoenig M, Ujhelyi MR, Miller AW. Cytochrome P450 activity and endothelial dysfunction in insulin resistance. J Vasc Res 2000;37:426-434 (Pubitemid 30774722)
20. 2+ signaling in glomerular mesangial cells in diabetes. Am J Physiol Renal Physiol 2007;293:F1381-90.
21. Snyder GD, Krishna UM, Falck JR, Spector AA. Evidence for a membrane site of action for 14,15-EET on expression of aromatase in vascular smooth muscle. Am J Physiol 2002;283:H1936-42.
22. Falck JR, Krishna UM, Reddy YK, et al. Comparison of the vasodilatory properties of 14,15-EET analogs: Structural requirements for dilation. Am J Physiol Heart Circ Physiol 2003;284:H337-49.
23. Gauthier KM, Jagadeesh SG, Falck JR, Campbell WB. 14,15-Epoxyeicosa-5(Z)- enoic-mSI: A 14,15- and 5,6-EET antagonist in bovine coronary arteries. Hypertension 2003;42:555-561
24. Wong PY-K, Lai P-S, Shen S-Y, Belosludtsev YY, Falck JR. Postreceptor signal transduction and regulation of 14(R), 15(S)-epoxyeicosatrienoic acid (14,15-EET) binding in U-937 cells. J Lipid Med Cell Signal 1997;16:155-169
25. Yang W, Tuniki VR, Anjaiah S, Falck JR, Hillard CJ, Campbell WB. Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125I-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 2008;324:1019-1027
26. Li P-L, Campbell WB. Epoxyeicosatrienoic acids activate potassium channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 1997;80:877-884
27. Li P, Chen C-L, Bortell R, Campbell WB. 11,12-Epoxyeicosatrienoic acid stimulates endogenous mono-ADP-ribosylation in bovine coronary arterial smooth muscle. Circ Res 1999;85:349-356
28. Dumoulin M, Salvail D, Gaudreault SB, Cadieux A, Rousseau E. Epoxyeicosatrienoic acids relax airway smooth muscles and directly activate reconstituted KCa2+ channels. Am J Physiol 1998;275:L423-31. (Pubitemid 28439736)
29. Gebremedhin D, Harder DR, Pratt PF, Campbell WB. Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: Role of a cytochrome P450 metabolite. J Vasc Res 1998;35:274-284 (Pubitemid 28368309)
30. + channel on pig coronary artery endothelial cells. J Physiol 1997;504:537-543
31. 2+ signaling complex with ryanodine receptors and BKCa channels. Circ Res 2005;97:1270-1279
32. 2+ entry in human and bovine endothelial cells. J Physiol 1995;482:259-274
33. 2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol 2007;27:2612-2618
34. Fisslthaler B, Hinsch N, Chataigneau T, et al. Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension 2000;36:270-275 (Pubitemid 30626999)
35. Gauthier KM, Deeter C, Krishna UM, et al. 14,15-Epoxyeicosa- 5(Z)-enoic acid: A selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 2002;90:1028-1036
36. Olearczyk JJ, Quigley JE, Mitchell BC, et al. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto Kakizaki rats. Clin Sci (Lond) 2009;116:61-70.
37. Balsinde J, Winstead MV, Dennis EA. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett 2002;531:2-6.
38. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131-185
39. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401:493-497 (Pubitemid 29470209)
40. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-1279 (Pubitemid 29398616)
41. Nithipatikom K, Pratt PF, Campbell WB. Determination of EETs using microbore liquid chromatography with fluorescence detection. Am J Physiol Heart Circ Physiol 2000;279:H857-62. (Pubitemid 30672800)
42. Huang A, Sun D, Jacobson A, Carroll MA, Falck JR, Kaley G. Epoxyeicosatrienoic acids are released to mediate shear stress-dependent hyperpolarization of arteriolar smooth muscle. Circ Res 2005;96:376-383 (Pubitemid 40279913)
43. Campbell WB, Holmes BB, Falck JR, Capdevila JH, Gauthier KM. Regulation of potassium channels in coronary smooth muscle by adenoviral expression of cytochrome P-450 epoxygenase. Am J Physiol Heart Circ Physiol 2006;290:H64-71.
44. Daikh BE, Lasker JM, Raucy JL, Koop DR. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther 1994;271:1427-1433
45. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996;271:3460-3468 (Pubitemid 26065653)
46. Zou AP, Fleming JT, Falck JR, et al. Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K(+)-channel activity. Am J Physiol 1996;270:F822-32.
47. Gauthier KM, Baewer DV, Hittner S, et al. Endothelium-derived 2-arachidonylglycerol: An intermediate in vasodilatory eicosanoid release in bovine coronary arteries. Am J Physiol Heart Circ Physiol 2005;288:H1344-51. (Pubitemid 40270043)
48. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol 1998;274:H375-81.
49. Fang X, Weintraub NL, Spector AA. Differences in positional esterification of 14,15-epoxyeicosatrienoic acid in phosphatidylcholine of porcine coronary artery endothelial and smooth muscle cells. Prostaglandins Other Lipid Mediat 2003;71:33-42. (Pubitemid 36428521)
50. Karara A, Wei S, Spady D, Swift L, Capdevila JH, Falck JR. Arachidonic acid epoxygenase: Structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem Biophys Res Commun 1992;182:1320-1325
51. Karara A, Dishman E, Jacobson H, Falck JR, Capdevila JH. Arachidonic acid epoxygenase. Stereochemical analysis of the endogenous epoxyeicosatrienoic acids of human kidney cortex. FEBS Lett 1990;268:227-230
52. Karara A, Dishman E, Falck JR, Capdevila JH. Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J Biol Chem 1991;266:7561-7569 (Pubitemid 21906402)
53. Chen J, Capdevila JH, Zeldin DC, Rosenberg RL. Inhibition of cardiac l-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 1999;55:288-295 (Pubitemid 29076025)
54. Fang X, Kaduce TL, Weintraub NL, et al. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 2001;276:14867-14874 (Pubitemid 37373365)
55. Fang X, Kaduce TL, Weintraub NL, VanRollins M, Spector AA. Functional implications of a newly characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res 1996;79:784-793 (Pubitemid 26317826)
56. Cowart LA, Wei S, Hsu M-H, et al. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator- activated receptor ligands. J Biol Chem 2002;277:35105-35112 (Pubitemid 35056076)
57. Spearman ME, Prough RA, Estabrook RW, et al. Novel glutathione conjugates formed from epoxyeicosatrienoic acids (EETs). Arch Biochem Biophys 1985;242:225-230
58. Carroll MA, Balazy M, Margiotta P, Falck JR, McGiff JC. Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J Biol Chem 1993;268:12260-12266 (Pubitemid 23182374)
59. Ellis EF, Police RJ, Yancey L, McKinney JS, Amruthesh SC. Dilation of cerebral arterioles by cytochrome P-450 metabolites of arachidonic acid. Am J Physiol 1990;259:H1171-7. (Pubitemid 20352318)
60. Zhang JY, Prakash C, Yamashita K, Blair IA. Regiospecific and enantioselective metabolism of 8,9-epoxyeicosatrienoic acid by cyclooxygenase. Biochem Biophys Res Commun 1992;183:138-143
61. Homma T, Zhang JY, Shimizu T, Prakash C, Blair IA, Harris RC. Cyclooxygenase-derived metabolites of 8,9-epoxyeicosatrienoic acid are potent mitogens for cultured rat glomerular mesangial cells. Biochem Biophys Res Commun 1993;191:282-288 (Pubitemid 23222633)
62. Gebremedhin D, Ma Y-H, Falck JR, Roman RJ, VanRollins M, Harder DR. Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am J Physiol 1992;263:H519-25.
63. Rosolowsky M, Campbell WB. Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol 1993;264:H327-35. (Pubitemid 23081099)
64. 2+-induced relaxation of rat mesenteric arteries. Am J Physiol 2008;294:H2363-70.
65. Coats P, Johnston F, MacDonald J, McMurray JJ, Hillier C. Endothelium-derived hyperpolarizing factor: Identification and mechanisms of action in human subcutaneous resistance arteries. Circ 2001;3:1702-1708 (Pubitemid 32246620)
66. Archer SL, Gragasin FS, Wu X, et al. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BKCa channels. Circ 2003;107:769-776 (Pubitemid 36222608)
67. Alkayed NJ, Narayanan J, Gebremedhin D, Medhora M, Roman RJ, Harder DR. Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke 1996;27:971-979 (Pubitemid 26142944)
68. Zeldin DC, Plitman JD, Kobayashi J, et al. The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: Characterization and significance. J Clin Invest 1995;95:2150-2160
69. Lapuerta L, Chacos N, Falck JR, Jacobson H, Capdevila JH. Renal microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Am J Med Sci 1988;295:275-279 . (Pubitemid 18130100)
70. Oltman CL, Weintraub NL, VanRollins M, Dellsperger KC. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 1998;83:932-939 (Pubitemid 28503082)
71. Nishikawa Y, Stepp DW, Chilian WM. In vivo location and mechanism of EDHF-mediated vasodilation in canine coronary microcirculation. Am J Physiol 1999;277:H1252-9.
72. Taddei S, Varsari D, Cipriano A, et al. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in human essential hypertensive patients. J Am Coll Cardiol 2006;48:508-515 (Pubitemid 44093964)
73. Pfister SL, Falck JR, Campbell WB. Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. Am J Physiol 1991;261:H843-52.
74. Pritchard Jr KA, Wong PY-K, Stemerman MB. Atherogenic concentrations of low-density lipoprotein enhance endothelial cell generation of epoxyeicosatrienoic acid products. Am J Pathol 1990;136:1383-1391
75. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circ 1996;94:3341-3347 (Pubitemid 26427507)
76. Larsen BT, Gutterman DD, Sato A, et al. Hydrogen peroxide inhibits cytochrome p450 epoxygenases: Interaction between two endothelium-derived hyperpolarizing factors. Circ Res 2008;102:59-67.
77. + channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins Other Lipid Mediat 2007;83:50-61.
78. Zygmunt PM, Högestätt ED. Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Br J Pharmacol 1996;117:1600-1606
79. 2+ permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 2005;97:908-915
80. Loot AE, Popp R, Fisslthaler B, Vriens J, Nilius B, Fleming I. Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation. Cardiovasc Res 2008;80:445-452
81. Hercule HC, Schunck WH, Gross V, et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009;29:54-60.
82. Nayeem MA, Poloyac SM, Falck JR, et al. Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice. Am J Physiol Heart Circ Physiol 2008;295:H2068-78.
83. Behm DJ, Ogbonna A, Wu C, Burns-Kurtis CL, Douglas SA. Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation. J Pharmacol Exp Ther 2009;328:231-239
84. Yang C, Kwan YW, Seto SW, Leung GP. Inhibitory effects of epoxyeicosatrienoic acids on volume-activated chloride channels in rat mesenteric arterial smooth muscle. Prostaglandins Other Lipid Mediat 2008;87:62-67
85. Fang X, Hu S, Xu B, et al. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. Am J Physiol Heart Circ Physiol 2006;290:H55-63.
86. Ohtoshi K, Kaneto H, Node K, et al. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem Biophys Res Commun 2005;331:347-350 (Pubitemid 40545182)
87. Zhao X, Li LY. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 2008;28:598-606. (Pubitemid 351832447)
88. 2+ entry in porcine aortic endothelial cells. Br J Pharmacol 1997;121:1579-1588
89. Bertrand-Thiebault C, Masson C, Siest G, Batt AM, Visvikis- Siest S. Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line. J Cardiovasc Pharmacol 2007;49:306-315 (Pubitemid 46855125)
90. Capdevila J, Gil L, Orellana M, et al. Inhibitors of cytochrome P-450-dependent arachidonic acid metabolism. Arch Biochem Biophys 1988;261:257-263 (Pubitemid 18078282)
91. Wang MH, Brand-Schieber E, Zand BA, et al. Cytochrome P450- derived arachidonic acid metabolism in the rat kidney: Characterization of selective inhibitors. J Pharmacol Exp Ther 1998;284:966-973 (Pubitemid 28130824)
92. Berhane Y, Bailey SR, Putignano C, Elliott J. Characterization of agonist-induced endothelium-dependent vasodilatory responses in the vascular bed of the equine digit. J Vet Pharmacol Ther 2008;31:1-8.
93. Falck JR, Reddy LM, Byun K, Campbell WB, Yi XY. Epoxygenase eicosanoids: Synthesis of tetrahydrofuran-diol metabolites and their vasoactivity. Bioorg Med Chem Lett 2007;17:2634-2638 (Pubitemid 46522519)
94. Lauterbach B, Barbosa-Sicard E, Wang MH, et al. Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension 2002;39:609-613 (Pubitemid 34165192)
95. Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC, VanRollins M. EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. Am J Physiol Heart Circ Physiol 2001;280:H2430-40. (Pubitemid 32553281)
96. Ye D, Zhang D, Oltman C, Dellsperger K, Lee HC, VanRollins M. Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J Pharmacol Exp Ther 2002;303:768-776 (Pubitemid 35231254)
97. Zeldin DC, Kobayashi J, Falck JR, et al. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 1993;268:6402-6407 (Pubitemid 23099336)
98. Zeldin DC, Wei S, Falck JR, Hammock BD, Snapper JR, Capdevila JH. Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: Substrate structural determinants of asymmetric catalysis. Arch Biochem Biophys 1995;316:443-451
99. Seubert JM, Xu F, Graves JP, et al. Differential renal gene expression in prehypertensive and hypertensive spontaneously hypertensive rats. Am J Physiol Renal Physiol 2005;289:F552-61. (Pubitemid 41208470)
100. Ai D, Fu Y, Guo D, et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 2007;104:9018-9023 (Pubitemid 47175429)
101. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 2002;63:1599-1608 (Pubitemid 34457999)
102. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007;292:C996-1012.
103. Luria A, Weldon SM, Kabcenell AK, et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 2007;282:2891-2898 (Pubitemid 47084334)